About: Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.
Sector: Healthcare
Industry: Biotechnology
Latest price: $0.49 (-8.22%)
APRE NASDAQ Aprea Therapeutics Inc
Aprea Therapeutics Inc share price
Atividade de preço de APRE
Último preço
$ 0,490
Variação (24h)
-0,04 USD (8,22%)
Volume
171.49K
Volume (média 4 sem.)
-
Abertura
$ 0,54
Variação do dia
$ 0,49 - $ 0,54
Fechamento anterior
$ 0,54
Último negócio
29 Oct, 8:00 pm GMT+0
Atrasado
29 Oct, 8:00 pm GMT+0
APRE price performance
Atrasado
29 Oct, 8:00 pm GMT+0
quote.marketSignals